SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TIPT, SMLR, FITB on Behalf of ShareholdersNEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
FLY-E CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Fly-E Investors to Contact the Firm Before the November 7th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fly-E (FLYE)To Contact Him Directly To Discuss Their Options
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates RYN, PCH, ATXS on Behalf of ShareholdersNEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to Contact the Firm Before November 7th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE and HI on Behalf of ShareholdersNEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
TRONOX CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Tronox Holdings Investors to Contact the Firm Before November 3rd DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Tronox (TROX) To Contact Him Directly To Discuss Their Options
Liangzhu, where time speaks: Expats explore roots of Chinese civilizationHangzhou, China, October 18, 2025 -- As the 3rd Liangzhu Forum opened in Hangzhou, capital of East China's Zhejiang province, on Oct 18, the ancient Chinese civilization once again came to the international spotlight.
DOW CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Dow, Inc. to Contact the Firm Before the October 28th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Dow To Contact Him Directly To Discuss Their Options
SEMLER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Semler Scientific Investors to Contact the Firm Before the October 28th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Semler (SMLR) To Contact Him Directly To Discuss Their Options
Trivolve Tech and Quixy Launch FMS, Bringing Forensic Management to the Cardano MainnetHyderabad, India, 18th October 2025, ZEX PR WIRE– Trivolve Tech, a blockchain and AI product studio, in collaboration with Quixy, a leading no-code/low-code enterprise platform, has officially launched its Forensic Management System (FMS) on the Cardano Mainnet. This marks a historic milestone in digital governance as the partnership brings blockchain-backed
LIFEMD CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds LifeMD Investors to Contact the Firm Before the October 27th DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeMD (LFMD) To Contact Him Directly To Discuss Their Options
NUTEX CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Reminds Nutex Health Investors of the October 21st Deadline for the Filed Class Action LawsuitBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nutex (NUTX) To Contact Him Directly To Discuss Their Options
A Turning Point for Humanity: Confronting Factory Farming and Embracing a Plant-Based FutureAcross continents and cultures, a quiet yet powerful transformation is unfolding — one that challenges how we eat, how we think about food, and how we define compassion in the modern world. For decades, factory farming has been the backbone of industrial food production. Today, it stands as one of the most urgent ethical, environmental, and public health crises of our time.
Class Action Announcement for Molina Healthcare, Inc. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Molina Healthcare, Inc. - Contact Kessler Topaz Meltzer & Check, LLPRADNOR, PA - October 18, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Molina Healthcare, Inc. (“Molina”) (
NYSE: MOH ) on behalf of those who purchased or otherwise acquired Molina securities between February 5, 2025, and July 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 2, 2025.
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
Merck (
NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2025 (Presentation #LBA3).
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) in patients with a high risk of disease recurrence. The trial compared ENHERTU with trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment.
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Merck (
NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy. These late-breaking data will be presented for the first time today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2025 (Presentation #LBA2) and were selected for an official Press Briefing.
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
Positive results from the DESTINY-Breast05 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and a high risk of disease recurrence. Results were presented today (LBA1) alongside the results of DESTINY-Breast11 (291O) in Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate. The trial compared ENHERTU followed by THP with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment.
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate when compared with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2 positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. Results were presented today (291O) alongside the results from the DESTINY-Breast05 (LBA1) phase 3 trial during Presidential Symposium I at the 2025 European Society for Medical Oncology (#ESMO25) Congress.
Medome Launches New Medical Industry: Personal Health Intelligence TM - AI-Powered Personal Health Records to Usher In New Era of DIY Healthcare for ALL AmericansMedome introduces a long awaited, first of its kind, AI-powered personal health record system, designed to prevent misdiagnosis and improve health outcomes with 24/7 access and affordability. Now everyone gets affordable access to expert medical intelligence.
NASDAQ: FFIV Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages F5, Inc. (NASDAQ: FFIV) Investors With Significant Losses to Contact the FirmRADNOR, PA - October 18, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) is currently investigating potential violations of the federal securities laws on behalf of investors of F5, Inc. (
NASDAQ: FFIV ) (“F5”).
Doylestown, PA Porsche Macan Transmission, Oil Change & 40k Service AnnouncedDoylestown Porsche Macan owners seeking dealer-grade servicing minus the high cost can now access it at a local European car specialist.
Doylestown Audi S4 40K Service, Oil Change & PCV Replacement: Auto Repair UpdateDoylestown Auto (267-279-9477), a trusted auto shop in high-performance vehicle care, has updated its Audi S4 40K service program.
Snap Inc. Deadline: Rosen Law Firm Urges Snap Inc. (NYSE: SNAP) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Snap Inc. (
NYSE: SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the “Class Period”). Snap is a technology company best known for Snapchat.
Infrrd Announces the Official Launch of Ally: The First Agentic AI Workforce for Mortgage Auditing
Infrrd, a global leader in AI-driven document processing solutions, has announced the official launch of Ally, the company’s pioneering Agentic AI workforce built exclusively for the mortgage industry.
Epomaker Unveils Magcore65 Lite: A Compact, Stable, and Durable Inductive KeyboardFeaturing a 65% layout and a high-strength ABS plastic case, the Epomaker Magcore65 Lite is a keyboard designed for those who prioritize stability and durability, offering a hardcore performance experience.
The New Standard in Investor Intelligence: SheetVenture’s Active Investors List Powers Global FundraisingDUBAI, AE – October 16, 2025 – SheetVenture today launched its real-time intelligence platform, setting a new standard for how founders access capital. By providing an active investors list that is constantly verified, the company replaces the broken startup investor database model with a live, accurate engine. This gives founders a direct line to VCs […]
University of Phoenix College of Social and Behavioral Sciences Leadership Publishes White Paper on Trauma-Informed Education
University of Phoenix College of Social and Behavioral Sciences announces a new white paper, “Trauma-Informed Education – A Pathway for Relief, Retention, and Renewal,” authored by College leadership Sheila Babendir, Ed.D., LPAC; Barbara Burt, Psy.D.; Michelle Crawford-Morrison, LMFT, LPCC, NCC; Samantha E. Dutton, Ph.D., LCSW-R; Christine Karper, Ph.D., LMHC (QCS); and MaryJo Trombley, Ph.D. The paper asserts that implementing trauma-informed practices can improve outcomes for students and educators, driving retention and well-being while equipping learners with skills they can carry into the workplace.
The Future Landscape of AI Innovation in the Future of Floor Plan and Home Design AI.The emergence of Floor Plan AI and Home Design AI is a turning point in the development of the sphere of architecture and interior design. Artificial intelligence is not a mere assistant in the creation of layouts or the proposal of color schemes anymore; it is quickly becoming the innovation that can imagine, design, and even […]
How Summit Trading Partners Helps You Ride the AI Wave and Conquer Wall StreetHow Summit Trading Partners Helps You Ride the AI Wave and Conquer Wall Street
Kaplan Fox Alerts Investors of CarMax, Inc. (KMX) to an Investigation of Possible Securities Law ViolationsNEW YORK, NY - October 18, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against CarMax, Inc. (“CarMax” or the “Company”) (
NYSE: KMX).
Kaplan Fox Alerts Investors of CarMax, Inc. (KMX) to an Investigation of Possible Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany.
Why Smart Travelers Shouldn’t Miss the TESSAN Voyager 205 Black Friday DealsLAS VEGAS, NV, NY / ACCESS Newswire / October 18, 2025 / TESSAN, which is at the forefront of global power solutions, is today seeing the launch of its latest product, the TESSAN Voyager 205, which the company is very excited to put forward, as it marks a large step forward in portable power tech. TESSAN has designed this for the increasing needs of professionals, travelers, and digital creators out there, and the Voyager 205 brings forth a new benchmark in compact yet powerful charging, which it achieves through the use of 205W GaN (Gallium Nitride) technology.
LendFriend Mortgage Unveils New Home Financing Programs to Meet Evolving Buyer NeedsAUSTIN, TX, NY / ACCESS Newswire / October 18, 2025 / LendFriend Mortgage, a trusted name in home financing, has launched a set of new home mortgage programs to make homeownership easier for modern earners, including self-employed professionals, business owners, and clients with high net worth.
Hi Relief Reports 500% Growth in 3 Months, Expands Global Reach to 5 MarketsLEWES, DE / ACCESS Newswire / October 18, 2025 / The global wellness economy surpassed $5 trillion in 2023 and continues to accelerate, according to Statista. With consumers increasingly choosing natural, lifestyle-oriented products they can buy online, direct-to-consumer brands are scaling quickly to capture demand.
X-VPN Issues Critical Security Advisory to Strengthen User Protection Against Blind In/On-Path AttacksSINGAPORE, SG, NY / ACCESS Newswire / October 18, 2025 / X-VPN, issued a security advisory addressing Blind In/On-Path ("path") attacks this week, outlining what the company has verified so far, actions already taken, and next steps with platform vendors. In simple terms, this refers to network path signals-clues on the route to the internet that may show a VPN is active, not decrypted content. It does not mean attackers can read messages or decrypt traffic. An independent review is underway to validate the scope and mitigations. X-VPN is operated by LIGHTNINGLINK NETWORKS PTE. LTD. in Singapore.
Cardano Price Prediction: Here's What Needs To Happen For ADA To New HighsAfter last week’s $19 billion crypto market crash, Cardano investors are watching closely to see if ADA can stage a comeback. The ADA price trades around $0.67, still recovering from heavy whale selling. Yet, analysts believe a breakout could be near if momentum returns.
SurviveX Launches Tea-Tree-Infused Hydrogel Burn Dressings — Instant Cooling Relief with Professional-Grade CareSurviveX launches its Tea-Tree-Infused Hydrogel Burn Dressings, providing instant cooling relief and natural healing for burns. Rated 4.8 stars from over 90 reviews, the sterile, non-stick pads offer professional-grade burn care that’s HSA-eligible and trusted by users for home, travel, and emergency use.
